作者
Jeffrey A. Allen,Jie Lin,Ivana Basta,Tina Dysgaard,Christian Eggers,Jeffrey T. Guptill,Kelly Gwathmey,Channa Hewamadduma,Remy Loris,Yessar Hussain,Satoshi Kuwabara,Gwendal Le Masson,Frank Leypoldt,Ting Chang,Marta Lipowska,Mark J. Lowe,Giuseppe Lauria,Luís Querol,Mihaela-Adriana Simu,Niraja Suresh,Anissa Tse,Peter Ulrichts,Benjamin Van Hoorick,Ryo Yamasaki,Richard A. Lewis,Pieter A. van Doorn
摘要
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system that can lead to severe disability from muscle weakness and sensory disturbances. Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective alternatives. Efgartigimod alfa, a human IgG1 antibody Fc fragment, has demonstrated efficacy and safety in patients with generalised myasthenia gravis. We evaluated the safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in adults with CIDP.